Literature DB >> 16187040

The effect of early treatment at the initial stage 3 moderate phase of retinopathy of prematurity on severe retinal changes.

Yoshikazu Hatsukawa1, Nami Ueki, Tomoko Yamagishi, Hiroyuki Kitajima.   

Abstract

PURPOSE: To compare the outcome of early treatment at the initial stage 3 moderate phase of retinopathy of prematurity (ROP) with that at prethreshold ROP.
METHODS: The outcome of treatment of 117 very-low-birth-weight infants was reviewed. Sixty-eight infants underwent their first treatment at prethreshold ROP (group A). The other 49 infants underwent their first treatment at the initial stage 3 moderate phase of ROP (pre-prethreshold ROP) (group B). The first treatment was performed by laser photocoagulation or cryotherapy. Eleven clinical variables were included in the evaluation of the two groups. The outcome of treatment of the two groups was compared as favorable or unfavorable. Logistic regression analysis was performed to assess the relation between each independent variable and an unfavorable outcome.
RESULTS: The extent of contiguous stage 3 moderate ROP and that of cumulative stage 3 moderate ROP were significantly smaller in group B. There were nine unfavorable outcomes in group A, but none in group B. Logistic regression analysis showed that the extent of cumulative stage 3 moderate ROP and the presence of zone 1 retinopathy were major predictive factors for unfavorable outcome in the treatment of very-low-birth-weight infants.
CONCLUSION: Early treatment at the initial stage 3 moderate phase of ROP decreases the occurrence of severe retinal changes.

Entities:  

Mesh:

Year:  2005        PMID: 16187040     DOI: 10.1007/s10384-004-0216-2

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  19 in total

1.  Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes.

Authors: 
Journal:  Pediatrics       Date:  2000-02       Impact factor: 7.124

2.  Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1988-04

3.  Early treatment of posterior retinopathy of prematurity: a controlled trial.

Authors:  J F Vander; J Handa; J A McNamara; M Trese; R Spencer; M X Repka; P Rubsamen; H Li; L S Morse; W S Tasman
Journal:  Ophthalmology       Date:  1997-11       Impact factor: 12.079

4.  Laser therapy for retinopathy of prematurity. Laser ROP Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1994-02

5.  Long-term follow up of visual acuity in eyes with stage 5 retinopathy of prematurity after closed vitrectomy.

Authors:  Y Fuchino; H Hayashi; T Kono; K Ohshima
Journal:  Am J Ophthalmol       Date:  1995-09       Impact factor: 5.258

6.  Causes of visual handicap in the Royal Blind School, Edinburgh, 1991-2.

Authors:  B W Fleck; Y Dangata
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

7.  An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity.

Authors: 
Journal:  Arch Ophthalmol       Date:  1984-08

8.  Outcomes after laser therapy for threshold retinopathy of prematurity.

Authors:  R Foroozan; B P Connolly; W S Tasman
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

9.  Refractive changes associated with scleral buckling and division in retinopathy of prematurity.

Authors:  D R Chow; P J Ferrone; M T Trese
Journal:  Arch Ophthalmol       Date:  1998-11

10.  Risk analysis of prethreshold retinopathy of prematurity.

Authors:  Robert J Hardy; Earl A Palmer; Velma Dobson; C Gail Summers; Dale L Phelps; Graham E Quinn; William V Good; Betty Tung
Journal:  Arch Ophthalmol       Date:  2003-12
View more
  1 in total

1.  Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.

Authors:  Huseyin Yetik; Murat Gunay; Sarkis Sirop; Ziya Salihoglu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-14       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.